I'm looking for non-dilutive funding for a biotech startup to cover clinical trials.

Yes. For a biotech startup, there are several non-dilutive routes that can fund clinical development, but the best fit depends heavily on your indication, trial phase, modality, and whether you're a U.S. small business.

Best options to investigate

• NIH/NCI/NIA/other NIH SBIR & STTR — probably the first place I'd look. These programs provide non-dilutive grants to small businesses for R&D, and SBIR/STTR were reauthorized in April 2026. The next standard NIH receipt date is September 5, 2026.
• FDA Orphan Products Clinical Trials Grants — particularly attractive if your therapy targets a rare disease. The program supports Phase 1, 2 and/or 3 clinical trials and is open to U.S. and foreign public/private entities, including for-profits. Current guidance permits up to $650K/year for four years, with potentially another $250K/year for qualifying innovative/efficient trial approaches. U.S. Food and Drug Administration The current RFA has a October 20, 2026 receipt date.
• BARDA / Project NextGen / BARDA DRIVe — worth investigating if you're developing a countermeasure, infectious-disease product, vaccine, diagnostic, or platform relevant to public health preparedness. These programs can use contracts and other mechanisms in addition to traditional grants.
• Department of Defense / DARPA / ARPA-H — potentially substantial non-dilutive funding if your technology maps onto a specific agency priority. ARPA-H in particular can be relevant to high-risk biomedical technologies, while DoD programs can be excellent for particular diseases, platforms, and dual-use technologies.
• Disease-specific foundations — for rare diseases and oncology in particular, foundations can provide grants or sponsored research funding that can be combined with federal awards. These are usually smaller than an NIH award but can help fund specific clinical milestones.

One important caveat

NSF America's Seed Fund is generally not the answer for paying for clinical trials. NSF explicitly excludes clinical trials from what it funds, although it can be excellent for the underlying technology/R&D before clinical development.

I can narrow this down substantially

If you give me these 5 details, I can research the currently open opportunities and build you a prioritized funding strategy:

1. Indication/disease
2. Modality — drug, biologic, gene therapy, cell therapy, diagnostic, device, etc.
3. Current clinical phase — pre-IND, Phase 1, Phase 2, Phase 3, etc.
4. Approximate amount needed — e.g. $2M, $10M, $30M
5. Company location — U.S. or elsewhere

I can then identify specific open grants/contracts, eligibility, maximum award amounts, deadlines, and which ones can realistically pay for your clinical trial, rather than giving you a generic list.

If you give me these 5 details, I can research the currently open opportunities and build you a prioritized funding strategy:

Securing non-dilutive funding for clinical trials is one of the toughest challenges in biotech, as most standard academic grants stop at preclinical phases. However, major federal agencies, public-private partnerships, and specialized accelerators do fund human clinical trials (Phase I-III) without taking equity.

The primary avenues for non-dilutive clinical trial funding include:

1. Federal Small Business Programs (NIH SBIR/STTR Fast-Track & Phase II)

• National Institutes of Health (NIH) Seed Fund: Offers SBIR and STTR Funding Opportunities specifically tailored for small businesses. While Phase I is usually preclinical, a Phase II or Fast-Track award (which combines Phase I and II) can provide significant multi-year funding suitable for early clinical validation/Phase I trials.
• Specialized NIH Institutes: Check individual institutes relevant to your therapeutic area (e.g., NCI for oncology, NIAID for infectious diseases) as they frequently issue targeted clinical trial NOFOs (Notices of Funding Opportunities).

2. Federal Accelerators & Defense/Health Security Agencies

• BARDA (Biomedical Advanced Research and Development Authority): Focuses on countermeasures for health security threats (pandemics, CBRN, antimicrobial resistance). BARDA routinely funds advanced development and late-stage clinical trials through large-scale contracts and OTA (Other Transaction Authority) vehicles, which are non-dilutive.
• CARB-X: If your biotech addresses drug-resistant bacterial infections, CARB-X provides non-dilutive funding and extensive support specifically designed to advance products through preclinical development and into human clinical safety trials.
• CDMRP (Congressionally Directed Medical Research Programs): Managed by the Department of Defense (DoD), programs like the Peer Reviewed Cancer Research Program or Military Medical Research program occasionally offer substantial clinical trial awards for dual-use technologies.

3. Disease-Specific Foundations & Patient Advocacy Groups

• The Cystic Fibrosis Foundation, JDRF (Type 1 Diabetes), Alzheimer's Drug Discovery Foundation (ADDF): Large disease foundations often run venture philanthropy arms. While some structured investments can be hybrid/convertible, many offer true milestone-based research grants or program-related investments dedicated specifically to pushing clinical stage assets across the "valley of death."

To help narrow down the best targets, tell me:

• What is your therapeutic area (e.g., oncology, infectious disease, rare disease)?
• What clinical phase are you raising for (Phase 0/I, Phase II)?
• Are you based in the US or internationally?

Yes. For a biotech startup, non-dilutive funding can cover a meaningful portion of clinical-development costs, but the best source depends heavily on the indication, modality, trial stage, and whether you already have an IND/IDE.

Best places to look

• NIH SBIR/STTR — usually the first place I’d investigate. NIH's small-business programs explicitly fund biomedical product development, including drugs, biologics, diagnostics, and devices. Current NIH opportunities include SBIR/STTR mechanisms with clinical trials permitted or required.

• NIH currently lists a standard SBIR Phase II ceiling of $2.154M and a Commercialization Readiness Pilot (CRP) ceiling of $4.191M, although individual institutes can have different limits and some topics qualify for higher-award waivers.

• If you've already demonstrated feasibility, Direct-to-Phase-II can let you bypass Phase I.

• STTR is particularly interesting if you have a university/hospital research partner; unlike SBIR, STTR requires a nonprofit research-institution partnership.

• NIH Commercialization Readiness Pilot (CRP). If you've already received qualifying NIH Phase II/Phase IIB funding, CRP can provide additional late-stage development support—potentially much more relevant to clinical-trial expenses than an early Phase I award.

• BARDA. If your product addresses pandemic influenza, emerging infectious disease, or chemical/biological/radiological/nuclear threats, BARDA can be substantially more significant than a conventional grant. Its programs can support development from preclinical work through clinical trials, manufacturing scale-up, and FDA approval.

• ARPA-H and other federal targeted programs. These can provide larger non-dilutive awards for ambitious biomedical technologies, but they tend to be highly mission- and solicitation-specific. I'd screen these alongside NIH rather than treating them as a generic grant source.

One important distinction

NIH's Phase I/II terminology is not the same thing as clinical Phase I/II/III. For example, an NIH SBIR Phase II award can fund work associated with a clinical trial; the NIH funding phase refers to the maturity of the R&D program, not the clinical-trial phase.

Also, NIH SBIR/STTR grants are genuinely non-dilutive: they don't require giving up equity, and NIH says the IP developed with the funds is retained by the company.

I can narrow this down substantially

If you give me these 5 pieces of information, I can identify the most promising current programs and likely award sizes:

1. Modality: therapeutic, biologic, cell/gene therapy, diagnostic, device, etc.
2. Indication/disease
3. Current stage: preclinical, IND-enabling, Phase I, Phase II, etc.
4. Approximate amount needed for the trial: e.g. $2M, $5M, $10M+
5. Whether you've previously received SBIR/STTR or other government funding

I can then research the current 2026 funding opportunities, including NIH institutes, BARDA, ARPA-H, disease-specific foundations, and state programs, and rank them by fit for your company.

If you give me these 5 pieces of information, I can identify the most promising current programs and likely award sizes:

Securing non-dilutive funding to cover the high costs of clinical trials is challenging—as standard SBIR Phase I/II grants usually target earlier-stage R&D —but several robust pathways exist specifically for clinical-stage biotech startups.

1. NIH Fast-Track and Phase IIB / Clinical Trials-Required Grants
   • While standard Phase I SBIR/STTR grants are small, many NIH institutes (like NCI, NHLBI, NIAID) issue specific Notices of Funding Opportunities (NOFOs) dedicated to clinical trials. Look into Phase IIB Bridge Awards or Clinical Trial-Specific SBIR awards , which can scale up funding significantly (often up to $3M–$4M+) to support mid-stage clinical validation. Check active listings via the NIH SEED Fund.
2. FDA Orphan Products Clinical Trials Grants
   • If your biotech targets a rare disease or condition, the FDA Office of Orphan Products Development (OOPD) provides highly competitive non-dilutive grants specifically to defray the costs of clinical trials for orphan products. These grants can fund phase I, II, or III trials.
3. BARDA (Biomedical Advanced Research and Development Authority)
   • If your therapeutic or diagnostic aligns with health security, anti-microbial resistance, pandemic preparedness, or CBRN threats, BARDA offers massive non-dilutive funding through milestone-based contracts rather than traditional grants. They routinely fund advanced clinical development and large-scale trials.
4. CDMRP (Congressionally Directed Medical Research Programs)
   • Managed by the Department of Defense (DoD), CDMRP funds medical research relevant to military health, specific cancers, neurodegenerative conditions, and autoimmune diseases. They frequently fund translational work and clinical trials that larger civilian bodies might pass over.
5. State-Level and Regional Translational Funds
   • Depending on your geography, state agencies like CIRM (California Institute for Regenerative Medicine) or similar state-backed life science venture funds offer substantial non-dilutive or recoverable grant funding specifically earmarked to push therapeutics through human clinical trials within that state.

To help narrow down the best specific targets, tell me:

• What therapeutic area or indication is your startup focusing on?
• What clinical phase (Phase I, Phase II, etc.) are you raising capital for?

Covering clinical trials with non-dilutive funding is the gold standard for preserving equity , though clinical work is notoriously expensive, meaning you have to target the heavy hitters in federal and philanthropic funding.

The primary non-dilutive avenues suited for clinical-stage biotech startups include:

1. NIH SBIR/STTR Phase II & Fast-Track Grants
   • The Details: While Phase I covers pre-clinical/feasibility work, Phase II and specialized mechanisms (like Phase IIB or Fast-Track) are explicitly designed to support human subjects and clinical trials. Budget caps for NIH Phase II awards routinely exceed $2M–$3M depending on the specific Institute or Center (e.g., NCI, NHLBI).
   • Where to look: Track active notices on the NIH SEED Fund portal. Note that you must explicitly look for "Clinical Trial Required" or "Clinical Trial Optional" funding opportunity announcements (FOAs).
2. BARDA (Biomedical Advanced Research and Development Authority)
   • The Details: If your therapeutic targets infectious diseases, medical countermeasures, radiologic threats, or pandemic preparedness, BARDA is a premier source. Unlike standard academic grants, BARDA typically funds via milestone-based, fixed-price contracts rather than traditional grants, often providing the multi-million dollar capital necessary to push assets through mid-to-late-stage clinical development.
   • Where to look: Monitor current industry solicitations and broad agency announcements (BAAs) via SAM.gov.
3. ARPA-H (Advanced Research Projects Agency for Health)
   • The Details: ARPA-H funds high-risk, high-reward biomedical and health breakthroughs that can create transformative societal change. They operate similarly to DARPA, utilizing milestone-driven contracts managed by dedicated program managers rather than standard study sections. If your clinical trial tests a paradigm-shifting platform or intervention, ARPA-H is worth targeting.
4. Venture Philanthropy & Disease-Specific Foundations
   • The Details: Foundations tied to specific indications (e.g., Cystic Fibrosis Foundation, JDRF, Leukemia & Lymphoma Society) frequently deploy venture philanthropy models. They provide substantial non-dilutive or recoverable grant funding explicitly to advance clinical assets down the pipeline for their specific patient populations.
   • Where to look: Identify foundations focused on your target disease area that explicitly list translational or clinical trial sponsorship programs on their research funding pages.
5. CDMRP (Congressionally Directed Medical Research Programs)
   • The Details: Managed by the Department of Defense, CDMRP funds targeted biomedical R&D across specific disease scopes—ranging from breast cancer and neurofibromatosis to traumatic brain injury. Several of their award mechanisms allow for substantial clinical trial implementation costs if the research aligns with military or public health relevance.

To help narrow down the best specific fit, what is your therapeutic area or indication (e.g., oncology, infectious disease, rare disease) and which clinical phase (Phase I, II, or III) are you looking to fund?

Yes. For a U.S. biotech, there are several non-dilutive paths that can realistically support clinical development, although the best fit depends heavily on your indication, modality, trial phase, and whether you already have an IND/IDE.

Best funding sources

1. NIH SBIR/STTR — probably your first place to look

NIH's SBIR/STTR programs are explicitly designed as non-dilutive funding for small life-science companies. Current NIH opportunities include clinical-trial-optional SBIR and STTR programs, and the programs were reauthorized in April 2026.

For 2026, NIH lists approximately:

• Phase I: up to $323,090
• Phase II: up to $2.15M
• Commercialization Readiness Pilot: up to $4.19M

Some topics qualify for higher award limits. Importantly, NIH's "Phase I/II" terminology is not the same thing as clinical-trial Phase I/II.

If you're already approaching or entering human trials, I'd look particularly closely at Phase II, Direct-to-Phase II, Fast Track, and the clinical-trial-specific opportunities, rather than assuming you need to start with Phase I.

2. FDA Orphan Products Clinical Trials Grants

If your biotech targets a rare disease, this can be one of the most directly relevant sources of non-dilutive clinical-trial money.

The program supports clinical trials of drugs, biologics, devices and certain medical foods addressing unmet needs in rare diseases. It can cover Phase 1, 2, and/or 3 trials.

Current FDA guidance says the standard budget is up to $650,000/year for up to four years, with an additional amount possible for innovative/efficient trial approaches, potentially reaching $900,000/year.

The key constraint is that the program is specifically for rare diseases/conditions and requires an IND or IDE for the clinical-trial grant.

3. BARDA / government contracts

If your product is relevant to pandemic preparedness, infectious disease, medical countermeasures, biodefense, or other government-priority threats, BARDA can be substantially larger than conventional grants.

This is particularly attractive because government contracts can fund development milestones and clinical development without taking equity.

4. Disease-specific NIH institutes

Don't just search "NIH SBIR." NIH has 24 institutes/centers participating in small-business funding, and the fit can vary dramatically by indication.

For example, NCI, NIAID, NHLBI, NIDDK, NINDS, NIAMS, etc. can have targeted opportunities that are much better aligned with particular clinical programs than the generic parent announcement.

A potentially important distinction

If your goal is specifically "pay for my clinical trial", I would rank the options roughly like this:

The FDA orphan program has actually helped fund trials leading to approval of more than 85 products, so it is worth investigating if your indication qualifies.

I can narrow this down substantially

If you give me these 5 details, I can research the currently available programs and identify the best-fit opportunities, including approximate award sizes and deadlines:

1. Modality: drug, biologic, cell/gene therapy, diagnostic, device, etc.
2. Indication/disease
3. Current clinical stage: pre-IND, IND-enabling, Phase 1, Phase 2, Phase 3, etc.
4. Approximate amount needed: e.g. $2M, $10M, $30M
5. U.S. company? (and roughly how many employees)

With those, I can also distinguish grants you can apply for as the company from programs that require an academic/nonprofit partner, which is an important practical difference.

If your biotech targets a rare disease, this can be one of the most directly relevant sources of non-dilutive clinical-trial money.

The program supports clinical trials of drugs, biologics, devices and certain medical foods addressing unmet needs in rare diseases. It can cover Phase 1, 2, and/or 3 trials.

Current FDA guidance says the standard budget is up to $650,000/year for up to four years, with an additional amount possible for innovative/efficient trial approaches, potentially reaching $900,000/year.

The key constraint is that the program is specifically for rare diseases/conditions and requires an IND or IDE for the clinical-trial grant.

3. BARDA / government contracts

If your product is relevant to pandemic preparedness, infectious disease, medical countermeasures, biodefense, or other government-priority threats, BARDA can be substantially larger than conventional grants.

This is particularly attractive because government contracts can fund development milestones and clinical development without taking equity.

4. Disease-specific NIH institutes

Don't just search "NIH SBIR." NIH has 24 institutes/centers participating in small-business funding, and the fit can vary dramatically by indication.

For example, NCI, NIAID, NHLBI, NIDDK, NINDS, NIAMS, etc. can have targeted opportunities that are much better aligned with particular clinical programs than the generic parent announcement.

A potentially important distinction

If your goal is specifically "pay for my clinical trial", I would rank the options roughly like this:

The FDA orphan program has actually helped fund trials leading to approval of more than 85 products, so it is worth investigating if your indication qualifies.

I can narrow this down substantially

If you give me these 5 details, I can research the currently available programs and identify the best-fit opportunities, including approximate award sizes and deadlines:

Yes. For a biotech company trying to pay for clinical trials without giving up equity, the strongest U.S. options are usually NIH SBIR/STTR and disease-specific federal programs, rather than general startup grants.

Best funding paths

NIH is probably your first place to look. Its SBIR/STTR program explicitly provides non-dilutive funding to life-science companies, and current NIH guidance lists a standard Phase II budget of $2,153,927 and a Commercialization Readiness Pilot (CRP) ceiling of $4,191,495.

Importantly, NIH has clinical-trial-specific opportunities. For example, current NIH opportunities include SBIR/STTR mechanisms specifically supporting implementation of clinical trials, while individual institutes have additional disease-specific mechanisms.

If you're already near the clinic

I'd prioritize programs roughly like this:

1. NIH SBIR Phase II / Phase IIB / CRP
Especially attractive if you've already generated strong preclinical data. The CRP can support things such as IND-enabling work, clinical studies, manufacturing, and regulatory assistance.

2. Disease-specific NIH institute funding
This can be substantially better than a generic SBIR if your indication fits a focused program. NIH currently has, for example, clinical-trial opportunities through NINDS, NIAID and other institutes.

3. DoD CDMRP
Potentially very attractive if your indication falls within one of its programs. For FY2026, for example, the Peer Reviewed Medical Research Program has a Clinical Trial Award with full applications due September 22, 2026, although the pre-application deadline has already passed. Other CDMRP programs have later deadlines—for example, the Ovarian Cancer Research Program's Clinical Trial Award has a September 15 pre-application deadline and October 1 application deadline.

4. BARDA
Worth investigating if your product addresses an infectious disease, pandemic threat, biodefense or other medical-countermeasure need. This can be particularly powerful for clinical development because BARDA can support substantially larger development programs than a conventional SBIR.

5. Strategic/academic partnerships
If you can structure the clinical program through an eligible academic partner, an STTR arrangement can sometimes unlock funding and clinical infrastructure that an SBIR-only strategy doesn't.

One important distinction

Don't automatically apply to NSF SBIR just because it's biotech. NSF explicitly excludes clinical trials from its program, and its biological-technologies solicitation says proposals primarily supporting clinical trials, clinical efficacy/safety studies, or clinical-stage drug candidates are noncompliant.

So if your immediate objective is "raise $2–10M to run a Phase 1/2 trial", NIH/disease-specific agencies and BARDA are much more interesting than NSF.

I can narrow this down substantially

If you give me these 5 things:

1. Indication/disease
2. Modality — small molecule, biologic, cell therapy, gene therapy, vaccine, diagnostic, etc.
3. Clinical stage — pre-IND, IND filed, Phase 1, Phase 2, etc.
4. Amount needed — e.g. $2M, $5M, $15M
5. Company status — U.S. C-corp/LLC and whether you've previously received an NIH SBIR/STTR award

…I can identify the specific non-dilutive programs you could realistically pursue now, including current 2026 deadlines, approximate award sizes, eligibility, and which ones can actually pay for the clinical trial itself.

Covering clinical trials with non-dilutive funding is challenging because trials are capital-intensive, but several major federal programs, foundations, and alternative structures specifically support clinical-stage biotech development.

• NIH SBIR/STTR Phase II & Fast-Track Grants
  The NIH SEED Fund offers small business innovation grants that allow clinical trials (designated explicitly as "Clinical Trial Required" or "Optional" in specific notices of funding opportunities). A Phase II award can provide upwards of $2M over 2 to 3 years, and Fast-Track options combine Phase I and Phase II to minimize the funding gap.
• BARDA (Biomedical Advanced Research and Development Authority)
  If your therapeutic aligns with health security, pandemic preparedness, antimicrobial resistance, or emerging infectious diseases, BARDA provides massive non-dilutive, milestone-based contracts. Programs like DRIVe (Division of Research, Innovation, and Ventures) offer smaller initial entry points (EZ-BAA) that can scale into tens of millions for advanced clinical development.
• CDMRP (Congressionally Directed Medical Research Programs)
  Managed by the Department of Defense, CDMRP funds a wide array of disease-specific research (including breast cancer, prostate cancer, neurodegenerative conditions, and trauma). While heavily academic, they frequently feature funding mechanisms specifically structured to support product development and clinical trials by small businesses.
• Venture Philanthropy and Disease Foundations
  Organizations like the Cystic Fibrosis Foundation, JDRF, or the Alzheimer's Drug Discovery Foundation (ADDF) provide equity-free funding, mission-aligned grants, and clinical trial networks for specific indications. They often require a success-fee or back-end return structure if the drug hits the market, but it remains strictly non-dilutive at the cap-table level.
• ARPA-H (Advanced Research Projects Agency for Health)
  ARPA-H funds high-risk, high-reward biomedical and health solutions. They utilize milestone-driven, project-based contracting akin to DARPA rather than traditional academic grants, making them a strong avenue for revolutionary clinical-stage platforms.
• R&D Tax Credits and State-Level Programs
  While not cash-in-hand for day-one trial execution, utilizing federal and state R&D Tax Credits can offset substantial portions of your payroll and operational burn, effectively stretching your available capital.

To help narrow down the best path, could you share:

• Your therapeutic indication or disease area?
• What clinical phase (Phase I, Phase II, etc.) you are fundraising for?
• Whether your company is U.S.-based?

Securing non-dilutive funding for clinical trials is challenging because clinical-stage work is expensive and exceeds standard small-grant caps . However, several major federal, philanthropic, and specialized avenues explicitly support human trials or late-stage translational development without taking equity.

• NIH SBIR/STTR Phase IIB and Fast-Track Grants : The NIH SEED Program offers Phase IIB (including the Strategic Breakthrough Award [R44]) which provides multi-million dollar, milestone-driven funding explicitly tailored to support clinical trials. Review the active NIH SBIR/STTR Funding Opportunities for clinical trial-optional mechanisms.
• BARDA (Biomedical Advanced Research and Development Authority) : If your therapeutic aligns with health security, pandemic preparedness, emerging infectious diseases, or CBRN threats, BARDA offers massive, non-dilutive milestone-based contracts and cooperative agreements that can deeply subsidize clinical development.
• ARPA-H (Advanced Research Projects Agency for Health): ARPA-H funds high-risk, high-reward biomedical and health breakthroughs. They routinely issue targeted solution-seeking solicitations that encompass clinical validation and translational studies.
• CDMRP (Congressionally Directed Medical Research Programs) : Managed by the Department of Defense, CDMRP allots billions annually to biomedical research spanning specific disease areas (e.g., breast cancer, prostate cancer, neurotrauma, peer-reviewed medical research). Many of their awards permit clinical trial funding if the focus matches their specific congressional line items.
• Venture Philanthropy and Disease Foundations : Foundations tied to specific indications (such as the Cystic Fibrosis Foundation, JDRF, or Alzheimer's Association) regularly deploy venture philanthropy models—providing substantial clinical-stage grants or rotable/non-dilutive trial funding if your asset targets their core mission.

If you share your therapeutic area (oncology, rare disease, infectious disease, etc. ) and your target clinical phase (Phase 1 vs. Phase 2 ), I can point you toward the most relevant specific agency or foundation programs for your pipeline.

Yes. For a biotech startup, the strongest non-dilutive clinical-trial funding routes are usually federal grants, especially if you can align the trial with a specific disease area or unmet need.

Best places to look

The FDA orphan-products program is particularly attractive if your indication qualifies: current guidance says awards can cover up to $650,000/year for up to four years, with potentially another $250,000/year for particularly innovative/efficient trial approaches.

NIH's SBIR/STTR programs have also recently been reauthorized through 2031, and NIH currently lists parent opportunities with clinical trials as an option, including an SBIR Phase IIB Strategic Breakthrough Award.

The important distinction

If you're already approaching an IND/clinical trial, don't assume a generic SBIR Phase I is the answer. The optimal strategy depends heavily on:

• Indication and patient population
• Drug vs. biologic vs. diagnostic vs. device
• Current development stage — preclinical, IND-enabling, Phase 1, Phase 2, etc.
• Whether you have an IND/IDE
• Size and duration of the proposed trial
• Whether the trial is pivotal or exploratory
• Whether you've already received NIH funding
• Whether you're partnered with an academic institution
• Whether the disease is rare/orphan
• Whether your technology fits a current ARPA-H/BARDA priority

For example, FDA's orphan-products clinical-trial program requires an IND or IDE and is specifically aimed at trials supporting approval/change in labeling for rare diseases with unmet needs.

If you give me (1) therapeutic area/indication, (2) modality, (3) current clinical phase, (4) approximate trial budget, and (5) whether you already have an IND, I can identify the specific grants and currently open 2026 opportunities most likely to fund your clinical trial, including deadlines, award sizes, eligibility, and application links.